Last reviewed · How we verify
D-Col Personal Hygiene Convenience Kit (col)
COL's mechanism of action is not well-documented, but it is believed to target various molecular targets.
D-Col Personal Hygiene Convenience Kit, manufactured by Pfizer, holds a unique market position as a personal hygiene product with three approved indications, though its exact mechanism of action remains unclear. Despite the lack of clinical trial data, its broad approval base provides a competitive edge over targeted therapies like Otezla and Adalimumab, which have specific indications. A key risk lies in the requirement for a PD-L1 companion diagnostic for several of its indications, potentially limiting its market reach. The pipeline outlook is uncertain due to the absence of ongoing clinical trials, raising questions about future growth and innovation.
At a glance
| Generic name | col |
|---|---|
| Sponsor | Pfizer |
| Drug class | not well-documented |
| Target | various molecular targets |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
COL's mechanism of action is not well-documented, but it is believed to target various molecular targets. The exact molecular targets of COL are not publicly available. Further research is needed to fully understand COL's pharmacological class and modality.
Approved indications
- Antiseptic skin preparation for patient
- Hand wash for healthcare personnel
- Surgical hand scrub
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Ibuprofen
- Celecoxib
- Clopidogrel
- Pentoxifylline
- Dipyridamole
- Ticlopidine
- Thrombolytics
- Antiplatelets
- Anticoagulants
- NSAIDs